Last reviewed · How we verify
BPZE1 pertussis vaccine and Boostrix
BPZE1 pertussis vaccine and Boostrix is a vaccine Biologic drug developed by ILiAD Biotechnologies. It is currently in Phase 2 development for Pertussis (whooping cough) prevention in adolescents and adults.
BPZE1 is a live attenuated pertussis vaccine designed to induce mucosal and systemic immunity against Bordetella pertussis, while Boostrix is a combined acellular pertussis booster vaccine.
BPZE1 pertussis vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It is used in combination with Boostrix, a pertussis vaccine, to provide protection against pertussis, also known as whooping cough.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BPZE1 pertussis vaccine and Boostrix |
|---|---|
| Sponsor | ILiAD Biotechnologies |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
BPZE1 is a genetically modified live vaccine strain that replicates in the respiratory mucosa to stimulate both cellular and humoral immune responses at the site of infection. Boostrix is an acellular pertussis vaccine containing inactivated toxins and surface antigens that provides booster immunity. The combination approach aims to enhance protective immunity against pertussis through complementary mechanisms.
Approved indications
- Pertussis (whooping cough) prevention in adolescents and adults
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (PHASE2)
- Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPZE1 pertussis vaccine and Boostrix CI brief — competitive landscape report
- BPZE1 pertussis vaccine and Boostrix updates RSS · CI watch RSS
- ILiAD Biotechnologies portfolio CI
Frequently asked questions about BPZE1 pertussis vaccine and Boostrix
What is BPZE1 pertussis vaccine and Boostrix?
How does BPZE1 pertussis vaccine and Boostrix work?
What is BPZE1 pertussis vaccine and Boostrix used for?
Who makes BPZE1 pertussis vaccine and Boostrix?
What drug class is BPZE1 pertussis vaccine and Boostrix in?
What development phase is BPZE1 pertussis vaccine and Boostrix in?
What are the side effects of BPZE1 pertussis vaccine and Boostrix?
Related
- Drug class: All vaccine drugs
- Manufacturer: ILiAD Biotechnologies — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Pertussis (whooping cough) prevention in adolescents and adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing